Although BRAF p.V600E mutations account for over 95% of all BRAF mutations identified in thyroid carcinoma (54), other non-V600E BRAF mutations, including substitutions or small insertion–deletions within the activation loop (residues 596–601) or in residues of the DFG (Asp–Phe–Gly) motif (residues 594–596), can also occur (67, 68, 69). Here, BRAF is linked to thyroid gland carcinoma.